Vaxcyte, Inc.

Vaxcyte reported $2.4 billion in cash, cash equivalents and investments as of December 31, 2025. Subsequent to year-end, it raised approximately $600.2 million in net proceeds from a public equity offering. Management said total spending increased in 2025 versus the prior year, driven mainly by commercial manufacturing readiness and clinical program advancement, and that 2026 total expenses, especially R&D, are expected to increase meaningfully versus both full-year 2025 and fourth-quarter 2025 annualized levels. The company did not state revenue or EPS on the call. Forward-looking, it expects OPUS-1 top-line safety, tolerability and immunogenicity data in the fourth quarter of this year, OPUS-2 and OPUS-3 readouts in the first half of 2027, and infant program top-line data by the end of the first half of 2027. It also said cash on hand, including the financing proceeds, provides runway to at least the end of 2028.

Grant Pickering framed 2025 as a year of focused execution that built the foundation for a catalyst-rich period ahead. He emphasized the unmet need in pneumococcal disease, arguing that VAX-31’s added serotype coverage and strong immunogenicity position it to set a new standard in adult PCVs. His tone was confident on the program, manufacturing, and commercialization build-out, while repeatedly stressing that the company does not need to be perfect on every serotype to support approval.

Andrew Guggenhime highlighted a strengthened balance sheet, with $2.4 billion in cash, cash equivalents and investments at year-end and roughly $600.2 million raised after year-end. He said the financing, combined with the current operating plan, gives Vaxcyte runway to at least the end of 2028 and supports multiple clinical, regulatory, and manufacturing milestones. On spending, he said 2025 expenses rose mainly because of manufacturing readiness and clinical development, and that 2026 expenses, particularly R&D, should rise meaningfully as the company scales commercial supply and runs more and larger trials; capitalized costs should decline as the dedicated manufacturing facility is now built out.

Analysts focused heavily on OPUS-1’s statistical design, including how comparisons against Prevnar 20 and Capvaxive are handled, and management said the study was designed in FDA consultation with broad confidence that totality of data can support licensure even if some serotypes miss. Questions also probed the potential for a catch-up recommendation, with management saying OPUS-3 is designed to show boosting of previously covered serotypes while preserving breadth, which could support ACIP discussions. Other notable topics were the infant dosing update, where management said higher-dose arms were added to improve serotypes that showed room for improvement, and Group A Strep, where management said Phase I will start in adults first and that there is no established correlative protection, so early work will focus on safety and immunogenicity rather than efficacy prediction.